Why not change classical treatments for glioblastoma in elderly patients?

doi:10.5493/wjem.v3.i4.50

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 3, Issue 4

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7395)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series.

Item

Count

PDF

513

HTML

4294

Figures (1-1)

162

Sum=4969

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1414

Download

1012

Sum=2426

Nov 20, 2013 (publication date) through Nov 22, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Experimental Medicine

ISSN

2220-315x

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Exp Med. Nov 20, 2013; 3(4): 50-55
Published online Nov 20, 2013. doi: 10.5493/wjem.v3.i4.50

Open in New Tab Full Size Figure Download Figure

Figure 1 Molecular targets propose for glioblastoma. EGFR: Epidermal growth factor receptor; ERK: Extracellularregulatedproteinkinases; ROS: Reactive oxygen species; VEGF: Vascularendothelialgrowthfactor.

Citation: Perez-Campos E, Perez JA, Mayoral LPC, Velasco IG, Cruz PH, Olivera PG. Why not change classical treatments for glioblastoma in elderly patients? World J Exp Med 2013; 3(4): 50-55
URL: https://www.wjgnet.com/2220-315X/full/v3/i4/50.htm
DOI: https://dx.doi.org/10.5493/wjem.v3.i4.50